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Recent evidence indicates that several members of the Na1-
coupled transporter family are regulated, and this regulation in
part occurs by redistribution of transporters between intracel-
lular locations and the plasma membrane. We elucidate com-
ponents of this process for both wild-type and mutant GABA
transporters (GAT1) expressed in Xenopus oocytes using a
combination of uptake assays, immunoblots, and electrophys-
iological measurements of membrane capacitance, transport-
associated currents, and GAT1-specific charge movements. At
low GAT1 expression levels, activators of protein kinase C
(PKC) induce redistribution of GAT1 from intracellular vesicles
to the plasma membrane; at higher GAT1 expression levels,
activators of PKC fail to induce this redistribution. However,
coinjection of total rat brain mRNA with GAT1 permits PKC-
mediated modulation at high transporter expression levels. This
effect of brain mRNA on modulation is mimicked by coinjection
of syntaxin 1a mRNA and is eliminated by injecting synapto-
physin or syntaxin antisense oligonucleotides. Additionally,
botulinum toxins, which inactivate proteins involved in vesicle
release and recycling, reduce basal GAT1 expression and pre-
vent PKC-induced translocation. Mutant GAT1 proteins, in
which most or all of a leucine heptad repeat sequence was
removed, display altered basal distribution and lack suscepti-
bility to modulation by PKC, delineating one region of GAT1
necessary for its targeting. Thus, functional regulation of GAT1
in oocytes occurs via components common to transporters and
to trafficking in both neural and non-neural cells, and suggests
a relationship between factors that control neurotransmitter
secretion and the components necessary for neurotransmitter
uptake.
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Plasma membrane neurotransmitter transporters use an electro-
chemical gradient for Na1 to move neurotransmitters across
membranes. Their location and capacity for removing neurotrans-
mitters suggest that transporters play an important role in synaptic
physiology (Iversen, 1975). Detailed analyses indicate that synap-
tic events could be influenced either by (1) the speed of rate-
limiting steps in the transport cycle; or (2) the density of trans-
porter molecules at the synapse (Mager et al., 1993; Sarantis et al.,
1993; Lester et al., 1994, 1996). Transporters are subject to reg-
ulatory mechanisms that affect each of these parameters, suggest-
ing that modulation of function may be important in transporter
function. For example, glutamate transport rates are modulated
by direct phosphorylation of the protein (Sardet et al., 1990;
Casado et al., 1993). Modulation by changes in transporter density
occurs for the facilitated glucose transporter: insulin increases
glucose transport by recruiting transporters from cytoplasmic ves-
icles to the plasma membrane (Cushman and Wardzala, 1980;
Suzuki and Kono, 1980).
We have demonstrated previously modulation of transport activity
for the rat brain GABA transporter GAT1 expressed in Xenopus
oocytes (Corey et al., 1994). Our conclusion that modulation occurs
via redistribution of the transporter between the cytoplasm and the
plasma membrane, similar to that shown for the facilitated glucose
transporter, is based on several observations. (1) Activation of pro-
tein kinase C (PKC) increases GABA transport, and this increase
correlates with an increase in the maximum velocity of transport
(Vmax). (2) Modulation does not affect the Km of the transporter. (3)
Subcellular fractionation of oocyte membranes reveals that upon
PKC stimulation, most transporters are associated with the plasma
membrane fraction; inhibition of PKC results in most transporters
being located intracellularly. More recently, the Na1-dependent glu-
cose transporter in epithelial cells (Delézay et al., 1995) and the
human serotonin transporter expressed in HEK-293 cells (Qian et
al., 1997) have been shown to be modulated by PKC-induced alter-
ations in cell surface transporter expression. The fact that modula-
tion by membrane trafficking, first identified for the facilitated glu-
cose transporter present in adipocytes and muscle cells (Cushman
and Wardzala, 1980; Suzuki and Kono, 1980), occurs for Na1-
coupled transporters expressed in epithelial cells and oocytes sug-
gests that there are common mechanisms present in different cell
types despite a lack of detailed amino acid similarity among these
transporters. We now extend our studies on the mechanisms of
GAT1 modulation based on factors shown to regulate trafficking and
expression of transporters in both neural and non-neural cells.
In this report, we use Xenopus oocytes to permit high-level expres-
sion of wild-type and mutant transporters, to identify trafficking
proteins affecting GAT1 expression, and to allow for detailed phys-
Received Aug. 9, 1996; revised Jan. 23, 1997; accepted Feb. 13, 1997.
This research was supported by United States Public Health Service Grants
NS-11756 (H.A.L.), DA-09121 (H.A.L.), DA-10509 (M.W.Q.), National Research
Service Award fellowships (M.W.Q. and J.L.C.), and the W. M. Keck Foundation
931360 (M.W.Q).
Correspondence should be addressed to Dr. Michael W. Quick, Department of
Neurobiology, CIRC 446, 1719 Sixth Avenue South, Birmingham, AL 35294-0021.
Dr. Corey’s present address: SIBIA, 505 Coast Boulevard South, La Jolla, CA
92037-4641.
Copyright © 1997 Society for Neuroscience 0270-6474/97/172967-13$05.00/0
The Journal of Neuroscience, May 1, 1997, 17(9):2967–2979
iological measurements of transporter modulation. We find (1) that
modulation of GABA transport is affected by coexpression of rat
brain mRNA; (2) that this effect requires proteins associated with
intracellular trafficking and secretion; (3) that the translocation pro-
cess underlying GAT1 modulation is affected by toxins known to
inhibit proteins required for neurotransmitter exocytosis; and (4) that
elimination of a leucine heptad repeat in the primary amino acid
sequence of GAT1 changes the basal distribution of GAT1 and
eliminates modulation by PKC.
MATERIALS AND METHODS
Materials. [3H]GABA was purchased from DuPont New England Nu-
clear. Phorbol 12-myristate 13-acetate (PMA), bisindolylmaleimide, and
botulinum toxins were obtained from Calbiochem. Horseradish peroxi-
dase (HRP)-conjugated donkey anti-rabbit Ig was purchased from Am-
ersham. All other reagents were obtained from Sigma. PMA and bisin-
dolylmaleimide were dissolved in ethanol and dimethyl sulfoxide,
respectively, and then diluted at least 100-fold in ND96 (96 mM NaCl, 2
mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, pH 7.4) before
oocyte injection. The botulinum toxins were obtained in 50 mM sodium
acetate and 200 mM NaCl, pH 6.0, at a concentration of 1 mg/ml and,
unless otherwise noted, diluted 20-fold in ND96 before injection. Human
syntaxin 1a (in pcDNAIII) was provided by Dr. K. Kirk (University of
Alabama at Birmingham), poly(A1) rat liver RNA was provided by Dr. P.
Chen (University of Alabama at Birmingham), and SKF89976A was a
generous gift of W. Bondinell (SmithKline Beecham).
Antisera. The polyclonal rabbit antiserum 342J (a gift from N. Brecha,
University of California, Los Angeles, CA) was generated against a
peptide corresponding to the carboxyl terminus (amino acids 588–599) of
the rat brain GABA transporter GAT1 (Guastella et al., 1990).
Mutagenesis of GAT1 and cRNA synthesis. Leucine-to-alanine muta-
tions (L83A, L90A, L97A, and L104A) were performed using the Clon-
tech Transformer Site-Directed Mutagenesis kit and verified by sequenc-
ing. RNA encoding GAT1 was synthesized using the Ambion Megascript
in vitro Transcription kit. The DNA template for the transcription reac-
tion was generated by PCR as described previously (Corey et al., 1994).
Rat brain RNA was extracted from fresh brains of 21-d-old rats using a
modified LiCl–urea procedure (Dierks et al., 1981). Poly(A1) RNA was
prepared by oligo-dT cellulose (type III, Collaborative Research) chro-
matography as described (Leonard et al., 1987).
Preparation of sense and antisense oligonucleotides. Synaptophysin oli-
gonucleotides were synthesized by the Caltech Oligonucleotide Synthesis
facility; syntaxin 1a oligonucleotides were synthesized by Cruachem.
Oligonucleotides were 19-mers selected from divergent regions in pub-
lished sequences. The rat synaptophysin (Sudhof et al., 1987) oligonucle-
otide was (sense strand, corresponding to bases 21 to 18) CATG-
GACGTGGTGAATCAG; the rat syntaxin (Bennett et al., 1992)
oligonucleotide was (sense strand, corresponding to bases 21 to 18)
GATGAAGGATCGGACTCAG. The oligonucleotides were phenol-
chloroform extracted, recovered by ethanol precipitation, and dissolved
in H2O.
Xenopus oocyte expression and transport assays. These methods are
described in detail elsewhere (Quick and Lester, 1994). Briefly, oocytes
were defolliculated and maintained at 18°C in ND96 supplemented with
2.5 mM sodium pyruvate, 50 mg/ml gentamycin, and 5% horse serum.
GAT1 cRNA (0.5–5 ng) was injected into each oocyte; 50 ng of poly(A1)-
selected rat brain RNA was used for the coinjection experiments. Assays
were performed 2–5 d postinjection. To standardize the drug delivery
procedure, all compounds were introduced into the oocyte by microin-
jection as described (Corey et al., 1994). Unless otherwise noted, 25 nl of
the following compounds were microinjected into GAT1-expressing oo-
cytes (approximate final concentrations): 400 nM PMA, 100 nM bisindolyl-
maleimide, 1 ng of botulinum toxin (BoNt)/B and BoNt/C, and 50 ng of
BoNt/A. To measure GABA uptake, oocytes were placed in ND96 to
which a final concentration of 260 nM [3H]GABA was added in timed
intervals. The reaction was terminated by removal of the oocyte and
multiple washes in ND96. The oocyte was then solubilized in 10% SDS,
and [3H]GABA uptake was determined by liquid scintillation counting.
For experiments involving coinjection of rat brain RNA, 20 mM bicucul-
line and 10 mM phaclofen were included with the extracellular GABA to
block potential responses attributable to GABA receptor stimulation.
Values in the text are expressed as the mean 6 SEM.
Electrophysiology. Two-microelectrode voltage-clamp procedures were
used (Quick and Lester, 1994). Whole-cell currents were measured using
either a Dagan 8500 or a GeneClamp 500 (Axon Instruments) amplifier.
Electrodes were filled with 3 M KCl and had a resistance of 1–2 MV.
Current was measured on-line by oscilloscope and chart recorder. Data
acquisition and analysis used the pClamp program suite (Axon Instru-
ments). Measurements of GAT1 charge movements were as described
(Mager et al., 1993). Briefly, the membrane potential was held at 240 mV
and jumped to 2100 mV for 1 sec. Each oocyte was tested in the presence
and absence of SKF89976A to isolate (by subtraction) the charge move-
ments associated with the presence of GAT1 in the plasma membrane.
The transient currents generated by these jumps were integrated to yield
the amount of charge movement in and out of the oocyte’s membrane
field. Surface transporter number was calculated using the equation:
N 5
Qmax
qzd,
where N is the number of transporters per oocyte, Qmax is the total charge
movement, q is the elementary charge, and zd is the sum total of the
distance that all charges move within the membrane field. We assumed
that the value of zd for the GAT1 transporter is 1.0 (Mager et al., 1993).
Membrane fractionation, electrophoresis, and immunoblot analysis.
These procedures are detailed by Corey et al. (1994). Briefly, oocytes
expressing GAT1 were injected with the modulatory compound(s) (25
oocytes per condition were injected within 10 min) and incubated for an
additional 20–50 min before homogenization. Oocytes were then homog-
enized, centrifuged, and layered on a discontinuous sucrose gradient.
After centrifugation, 1 ml fractions were collected from the bottom of the
gradient. Previous analyses indicated that GAT1 was found only in
fractions enriched for plasma membrane (fractions 5 and 6) and trans-
Golgi/cytoplasmic vesicles (fractions 9 and 10) (Corey et al., 1994).
Therefore, fractions 5 and 6 were pooled and fractions 9 and 10 were
pooled within each condition. The pooled samples were diluted sixfold
with 0.15 M sucrose in TE buffer (10 mM Tris, 1 mM EDTA). The
remaining samples were diluted 12-fold with the same buffer, pelleted by
centrifugation, resuspended in 20 ml sample buffer (Laemmli, 1970), and
stored at 280°C. Proteins in the microsomal membrane fractions were
separated by SDS-PAGE on 10% gels and electrophoretically transferred
to polyvinylidene difluoride membrane (Pierce). The immunoblotting
procedure included a 60 min incubation with the polyclonal antibody
against GAT1 (342J) diluted 1:200 and a 30 min incubation with HRP-
conjugated donkey anti-rabbit Ig antibody diluted 1:1000. A 67 kDa band,
shown to be GAT1 (Corey et al., 1994), was detected by visualization
using electrochemiluminescence reagents (Amersham). Only the pooled
fractions enriched for the plasma membrane and cytoplasmic vesicles are
shown in the figures. The other fractions were run separately, and no
GAT1 immunoreactivity was detected in any of the samples (data not
shown).
RESULTS
Coinjection of rat brain mRNA permits PMA-induced
modulation of GAT1 at high expression levels
Previous data examining GAT1 modulation showed that as trans-
porter expression increased, PKC induced a smaller fractional
increase in transport, even though PKC still induced translocation
of GAT1 from the intracellular stores to the plasma membrane
fraction (Corey et al., 1994). This suggested that some component
of the oocyte machinery necessary for functional surface trans-
porter expression was being saturated. We tested this hypothesis
in experiments using various combinations of GAT1 cRNA injec-
tions, rat brain poly(A1)-selected mRNA injections 1–5 d before
uptake measurements, and drug injections to manipulate PKC
10–15 min before the uptake assay. These results are shown in
Figure 1. Figure 1A (top) shows the effect of PKC manipulations
on [3H]GABA uptake for a single batch of oocytes (examined 24
hr after RNA injection) expressing comparatively low levels of
transporter (as determined by basal [3H]GABA uptake activity),
although transport was still 20-fold higher than for oocytes not
injected with GAT1 cRNA. In this experiment, a saturating con-
centration of the PKC activator PMA increased uptake ;70%
2968 J. Neurosci., May 1, 1997, 17(9):2967–2979 Quick et al. • Functional Regulation of a GABA Transporter
Figure 1. PMA-induced modulation of GAT1 uptake. A, Coinjec-
tion of rat brain mRNA allows PMA-induced GAT1 modulation at
higher expression levels. Oocytes were injected with 5 ng of GAT1
cRNA alone or in combination with 50 ng of rat brain mRNA, then
assayed by [3H]GABA uptake. The assay time was 15 min. Data
represent an experiment (5–7 oocytes per condition, mean 6 SEM) for
oocytes from a single batch, examined either at 1 d (low expression;
top) or at 5 d (high expression; bottom) after RNA injection. Before the
assay, oocytes were injected with 25 nl of a vehicle solution (Basal, open
bars) or a solution containing 400 nM PMA (15 min before assay,
hatched bars) or 100 nM bisindolylmaleimide (BIS; 10 min before assay,
filled bars). Note that the top and bottom panels have different vertical
scales. B, Summary of data for the effect of rat brain mRNA coinjec-
tion. Expression level is quantified as the amount of [3H]GABA
uptake in GAT1 RNA-injected oocytes ( filled circles) or GAT1 and rat
brain RNA-injected oocytes (open circles) injected with vehicle solu-
tion 15 min before assay (abscissa). The change in uptake induced by
400 nM PMA (ordinate) is plotted as a percentage of vehicle-only
injected oocytes. Each data point represents the mean 6 SEM for
three to seven oocytes. Expression levels were varied by injecting
different amounts of GAT1 cRNA and by performing the assay at
different translation times after RNA injection. C, PMA modulation
shows specificity for GAT1 and rat brain mRNA. Oocytes from the
same frog were injected with 5 ng of GAT1 cRNA in combination with
either 50 ng of rat brain mRNA or 50 ng of rat liver mRNA; or, oocytes
were injected with 25 ng of cRNA encoding the rat homomeric nicotinic acetylcholine receptor a7 in combination with 50 ng of rat brain cRNA.
For the GAT1 cRNA-injected oocytes, GABA transport was assessed as described in A. For oocytes expressing a7, peak currents induced by
perfusion of 200 mM nicotine were measured using a two-electrode voltage clamp. The holding potential was 270 mV. The change in function
induced by 400 nM PMA (hatched bars) is plotted as a percentage of vehicle-only treated oocytes (open bars). Each data point represents the
mean 6 SEM for seven oocytes. D, Differential effects of PMA administration on GAT1 uptake. Oocytes were injected with 5 ng of GAT1 cRNA
and assayed (5 oocytes per condition) for [3H]GABA uptake after bath application ( filled circles) or injection ( filled squares) with 400 nM
PMA. The change in uptake (right ordinate) is plotted as a percentage of vehicle-only treated oocytes. The resting membrane potential for subsets
(5 each) of PMA-incubated (open circles) and PMA-injected (open squares) oocytes was monitored electrophysiologically. The results are plotted
as a percentage of their resting membrane potential before PMA application (left ordinate).
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above the level for GAT1-expressing oocytes injected with water
rather than with PMA. The PKC inhibitor bisindolylmaleimide
blocked basal activity by ;50%. These data reproduce our earlier
observations (Corey et al., 1994). Figure 1A also shows that
coinjection of 50 ng of rat brain mRNA with the GAT1 cRNA did
not change the modulation observed at low expression levels. The
quality of the rat brain mRNA was verified by both [3H]GABA
(twofold above background) and [3H]glutamate (sixfold over
background) uptake assays in oocytes injected with the rat brain
mRNA alone (data not shown).
The bottom panel of Figure 1A summarizes a comparable
experiment on oocytes from the same batch at comparatively
higher transporter expression levels (5 d after RNA injection).
For oocytes injected with only GAT1 cRNA, PMA did not induce
an increase in GABA uptake. However, the addition of rat brain
mRNA permitted an increase in [3H]GABA transport at high
expression levels; this fractional increase (68% higher than basal
levels) was comparable to the effects seen with GAT1 alone at low
expression levels. It should be noted that at high GAT1 expression
levels, the amount of GABA transport resulting from the injection
of rat brain mRNA is only ;1% of that resulting from GAT1
cRNA-mediated uptake, and therefore cannot account for the
increase in PMA-induced transporter function.
Figure 1B compares PMA-induced functional modulation be-
tween oocytes injected with GAT1 cRNA alone and oocytes
injected with both GAT1 cRNA and rat brain mRNA. These data
represent experiments performed using oocytes from a number of
batches. Rat brain mRNA allows modulation at high expression
levels whether obtained by increasing the amount of GAT1 cRNA
injected or by increasing the postinjection translation time before
assay.
Two experiments were performed to assess the specificity of
PMA-induced modulation of GAT1 function after coexpression
of rat brain mRNA. These results are shown in Figure 1C. In
oocytes expressing basal transport levels of approximately 100
fmol /oocyte/min (compare with the bottom of Fig. 1A), the PMA-
induced increase in GABA transport occurs in oocytes expressing
GAT1 and rat brain mRNA, but not in oocytes expressing GAT1
and rat liver mRNA. These data suggest that some component in
the brain mRNA, rather than a nonspecific effect of RNA loading,
is responsible for the increases in GABA transport. To test
whether this effect is specific to the transporter, we coexpressed
rat brain mRNA with another brain membrane protein, the
ligand-gated neuronal nicotinic receptor a7. PMA failed to induce
a change in nicotine-induced a7-mediated currents as assessed by
two-electrode voltage clamp (mean inward currents for oocytes in
the basal state at 270 mV were 235 nA).
In addition to the translocation of GAT1 by PMA observed in
our studies, independent investigations have shown that, under
certain conditions and in different cell types, phorbol esters can
exert other effects on GABA transporter function, including: (1)
increasing the Km for GABA in oocytes twofold (Osawa et al.,
1994); and (2) decreasing Vmax 50% (at GABA concentrations .1
mM) in 293 cells (Sato et al., 1995). To further understand the
mechanisms underlying these multiple effects of phorbol ester
treatment and to minimize their impact on the present studies, we
examined changes in [3H]GABA uptake and resting membrane
potential after different PMA applications. These results are
shown in Figure 1D. In agreement with other studies, there was a
decrease in GABA uptake of 20–30% in oocytes when PMA was
bath-applied. This decrease in uptake correlated with a substan-
tial decrease in the membrane potential of the oocyte (i.e., the
membrane potential became less negative) over the same time
course. This decrease of the membrane potential was not ob-
served in oocytes injected with PMA, except for a small decrease
most likely attributable to the injection process. The delay in both
effects, membrane potential and GABA uptake, compared with
cytoplasmic injection of PMA, is consistent with the time required
for the activator to cross the plasma membrane. These data show
that bath application of PMA decreases GABA uptake primarily
by decreasing the Na1 driving force. In agreement with other
studies, we also find that the effect attributable to bath application
of PMA is specific; it is reversed with PKC inhibitors (data not
shown). Thus, the data suggest that PKC affects transporter func-
tion via multiple pathways that occur over different time courses.
To date, we have not investigated possible changes in GAT1
subcellular distribution after bath application of PMA, nor have
we investigated the effect of bath application of PMA over longer
incubation times.
Electrophysiological analysis of GAT1 modulation
Electrophysiological analysis of GAT1 function is practical only at
high expression levels. Because coinjection of rat brain mRNA
conferred the ability to modulate GABA transport at high expres-
sion levels, it was possible to characterize modulation electro-
physiologically. One such set of traces is shown in Figure 2A. In
this example, the oocyte was voltage-clamped at 280 mV and
superfused with GABA for 10 sec. In the basal condition (no
PMA), GABA induced a peak inward current of ;90 nA. Con-
sistent with the uptake data, the transport-associated currents
were approximately twofold larger after PMA injection. The
transport-associated currents were completely blocked by the
specific GABA transport inhibitor SKF89976A (Yunger et al.,
1984), showing that the basal and PMA-enhanced currents were
attributable to GABA transporter function. The voltage depen-
dence of basal and PMA-induced currents reveals the pronounced
inward rectification characteristic of transporter-associated cur-
rents (Fig. 2B).
Previous dose–response analysis of GABA transport in oocytes
expressing GAT1 alone suggested that modulation changes the
Vmax of transport rather than the EC50 (Corey et al., 1994).
Because oocytes coinjected with GAT1 and rat brain mRNA
showed larger transport-associated currents (and therefore al-
lowed more precise measurements), we extended the earlier
dose–response studies and Eadie–Hofstee transformations of
basal and PMA-injected oocytes (Fig. 3A). The PMA modulation
was associated with a change in the Vmax of transport. This
observation agrees with the earlier data and is also consistent with
an increase in GAT1 protein in plasma membrane fractions as
assessed by Western blot (Fig. 3A, inset). No differences in gel
mobility were distinguishable in immunoblots between oocytes
injected with GAT1 cRNA alone or in combination with rat brain
mRNA (data not shown); thus, even when coexpressed with rat
brain mRNA, GAT1 is not glycosylated in oocytes (Guastella et
al., 1990).
Although the kinetic analysis and immunoblot data discussed
above provide strong evidence for modulation attributable to
changes in functional surface transporter expression, the ability to
modulate the transporter at high expression levels permits direct
assessment of this hypothesis based on the fact that each trans-
porter contributes an increment of charge movement in a voltage-
jump experiment. The rationale for charge movement measure-
ments has been presented in detail previously (Mager et al., 1993,
1996). Briefly, in response to a voltage jump, a transient (100–150
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msec) current flows in oocytes injected with GAT1, but not in
uninjected or water-injected oocytes. The time integral of the
currents is a charge movement. In the absence of GABA, this
charge movement is equal and opposite for reciprocal jumps; i.e.,
it is purely capacitive and occurs because ions move into and out
of the membrane dielectric while binding to the transporter.
Importantly, the charge movements are blocked by the GABA
transporter-specific inhibitor SKF89976A. Therefore, the GAT1-
specific charge movements can be isolated by subtracting current
traces measured in the presence and absence of SKF89976A. As
described in Materials and Methods, this charge movement dif-
ference attributable to transporter expression can be converted to
surface transporter number.
Analysis of modulation by charge movement measurements,
however, is complicated slightly by a nonspecific reduction in
membrane area induced by PMA (Bourinet et al., 1992; Schmal-
zing et al., 1995). Figure 3B shows that SKF89976A subtraction
nonetheless avoids distortion from this effect. In oocytes injected
with rat brain mRNA alone, PMA induces a reduction in oocyte
membrane capacitance of ;35%. This reduction in capacitance
also occurs in uninjected and water-injected oocytes (data not
shown). Superfusion of SKF89976A has no measurable effect on
the membrane capacitance in rat brain mRNA-injected oocytes,
even though it is probably blocking the relatively small amount of
GAT1 that is encoded by the rat brain mRNA. The coinjection of
GAT1 cRNA with rat brain mRNA results in less reduction in
membrane capacitance attributable to PMA injection; i.e., com-
pared with PMA-injected control oocytes, there is an increase in
capacitance in GAT1-coexpressing oocytes. This increase in ca-
pacitance is completely blocked by superfusion of SKF89976A,
suggesting that the difference in capacitance measured before and
after SKF89976A application is attributable to the GAT1 charge
movements. An alternative method, to avoid the nonspecific ca-
pacitance changes attributable to membrane retrieval, relies on
the fact that the passive capacitive currents are much faster (time
constant of ,5 msec, depending on the speed of the voltage-
clamp circuit) than the GAT1 charge movements (time constants
of 50–100 msec) (Mager et al., 1993, 1996). The GAT1 charge
movements can therefore be determined by beginning the inte-
gration ;5 msec after the voltage jump. This method yields
equivalent results to the SKF89976A subtraction method (data
not shown).
Thus, charge movements provide a measure of changes in
functional transporter number on the cell surface during modu-
lation. Figure 3C shows that these measurements explain the lack
of modulation of PMA in oocytes expressing GAT1 alone at high
levels, even though PMA does induce translocation of the trans-
porter protein to the plasma membrane fraction (Corey et al.,
1994). In oocytes coinjected with GAT1 cRNA and rat brain
RNA, PMA induces a time-dependent increase in functional
surface transporter number compared with vehicle-injected con-
trols. In contrast, oocytes injected with GAT1 cRNA only, and
expressing at high levels, fail to show increases in functional
surface transporters in response to PMA. A simple interpretation
of these results is that (1) increasing quantities of GAT1 saturate
a component necessary for GAT1 expression; and (2) rat brain
RNA provides components necessary for functional surface ex-
pression of large quantities of GAT1 after translocation to the
plasma membrane fraction.
The above conclusions are strengthened by examining the re-
lationship among our three measures of GABA transporter traf-
ficking and function. These data are shown in Figure 3D. A single
batch of oocytes was injected with GAT1 and rat brain cRNA.
These oocytes were then assayed by uptake, charge movement
measurements, and immunoblot over 5 consecutive d postinjec-
tion. The uptake and charge movement measurements show a
nearly superimposable rise, suggesting that the modulation of
uptake is indeed attributable to a change in functional transporter
Figure 2. Electrophysiological characterization of PMA-induced GAT1 modulation and block by SKF89976A. A, Two-electrode voltage-clamp analysis
of GABA-induced currents for a GAT1/rat brain mRNA-injected oocyte. The holding potential was 280 mV. The solid bar above the traces represents
the application of 100 mM GABA. Bicuculline (20 mM) and phaclofen (10 mM) were included to block potential responses attributable to GABA receptor
stimulation. PMA (400 nM) was injected after measurement of the basal condition; the PMA-induced trace was recorded 20 min later. The response in
the presence of 10 mM SKF89976A was recorded 5 min later. B, Current–voltage relationship for another oocyte recorded as described in A and subjected
to voltage ramps from 2100 mV to 140 mV over 1 sec.
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Figure 3. PMA-induced modulation occurs by increasing surface transporter expression. Oocytes were injected with 5 ng of GAT1 cRNA and/or 50 ng
of rat brain mRNA and assayed 4 d postinjection. PMA (25 nl; 400 nM) was injected 15 min before assay. A, Eadie–Hofstee transformation of
dose–response [3H]GABA uptake data for basal (open circles) and PMA ( filled circles) conditions (5 oocytes per condition). The assay time was 15 min.
GABA concentrations were 0.5, 1, 2, 4, 8, and 16 mM. The average SEM across all conditions was 16.4% of mean values. Inset shows PMA-induced
translocation of GAT1 as assessed by Western blot. B, Changes in cell capacitance associated with PMA injection. Membrane potential was held at 240
mV and stepped to 2100 mV for 1 sec in the presence ( filled bars) and absence (open bars) of 10 mM SKF89976A. Capacitance data are presented as
a percentage of the basal capacitance measured before PMA injection. Five oocytes were tested in each of the injection conditions; each oocyte was tested
in the absence and presence of SKF89976A. C, PMA-induced (circles) changes in oocyte plasma membrane transporter number as assessed by
measurement of charge movements. Calculations are described in Materials and Methods. Oocytes were injected either with 5 ng of GAT1 cRNA alone
( filled symbols) or GAT1 cRNA plus 50 ng of rat brain mRNA (open symbols). Oocytes in the basal condition (squares) were control-injected with 25 nl
of water. The data presented are from individual oocytes with comparable initial charge movements and are representative of five oocytes /condition. D,
Comparison of GABA uptake, surface GABA transporter number, and plasma membrane protein levels. Oocytes from a single frog were injected with
5 ng of GAT1 cRNA and 50 ng of rat brain mRNA and assayed for 5 consecutive d. [3H]GABA uptake (squares) assays were 15 min (5 oocytes /data
point). Surface transporter number (circles) was calculated from GAT1-specific charge movements as described in Materials and Methods (5 oocytes /data
point). Subcellular fractionation was performed on parallel oocyte samples (25 oocytes /sample) and analyzed by immunoblot as described in Materials
and Methods. GAT1 protein present in plasma membrane (triangles) was measured by densitometry (nominal units). All data are plotted relative to the
values obtained on day 1.
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number. Protein levels of GAT1 also increased over this time
period; however, these results were less precise and showed
greater variability. Therefore, these data also remain consistent
with the possibility that transporter protein levels in the plasma
membrane fraction do not precisely parallel functional surface
transporter number or transport rates. We suggested previously
that there is an additional, inactive state of the transporter in the
plasma membrane fraction (Corey et al., 1994).
Role of trafficking-related proteins in modulation of
GABA transport
Two lines of evidence suggested the hypothesis that components
involved in vesicle exocytosis and recycling and in protein traf-
ficking may be involved in transporter trafficking and expression,
and that these may be the limiting factor in oocytes. First, the
trafficking of transporters for intracellular storage, their regulated
expression on the plasma membrane, and their modulation of
expression by second messengers parallel events that occur during
vesicle secretion and protein trafficking (Bennett et al., 1992; Blasi
et al., 1993b). Second, these components must be added exog-
enously to oocytes to reconstitute neurotransmitter secretion (Al-
der et al., 1992).
To address this possibility, we used an antisense strategy to
eliminate PMA-induced modulation at high transporter expres-
sion levels in oocytes coinjected with GAT1 and rat brain RNA.
The results using antisense oligonucleotides to the trafficking
proteins synaptophysin and syntaxin 1a are shown in Figure 4.
Sense and antisense oligonucleotides corresponding to divergent
sequences of these proteins were synthesized and individually
injected into oocytes. Standard [3H]GABA uptake assays in oo-
cytes expressing high amounts of the transporter showed that
antisense synaptophysin and antisense syntaxin 1a oligonucleo-
tides eliminated the PMA-induced modulation of GAT1 present
in control oocytes injected with sense oligonucleotides (Fig. 4A).
Syntaxin, a plasma membrane component of the vesicle docking /
fusion complex (Bennett et al., 1992), is selectively cleaved by
BoNt /C (Blasi et al., 1993b). PMA-induced modulation of trans-
port in sense syntaxin oligonucleotide-injected oocytes was elim-
inated by injection of BoNt /C before assay. In addition, there was
a small decrease in uptake in oocytes injected with antisense
syntaxin oligonucleotides (see Fig. 5). Neither injection of anti-
sense syntaxin 1a oligonucleotides nor BoNt /C affected nicotine-
induced currents in oocytes expressing the a7 acetylcholine re-
ceptor (data not shown).
In examining the role of synaptophysin in PMA-induced mod-
ulation of the transporter as a function of expression level, we
found that the results for GAT1 and rat brain coinjected oocytes
treated with synaptophysin antisense oligonucleotides closely re-
sembled the pattern of results for oocytes injected with GAT1
cRNA alone (Fig. 4B). These results suggest that synaptophysin is
at least one component of rat brain mRNA that permits PMA-
induced modulation of GAT1 at high expression levels. Charge
movement measurements revealed that antisense synaptophysin
oligonucleotides blocked the expected PMA-induced increase in
functional surface transporter number (Fig. 4C).
To determine whether these trafficking proteins were sufficient
to confer PKC-induced modulation of GAT1 at high expression
levels, we injected GAT1 cRNA alone or in combination with
cRNA encoding human syntaxin 1a (Fig. 4D). Coinjection of
syntaxin 1a by itself caused an increase in basal GABA transport
(;30% above GABA transport in oocytes injected with GAT1
alone), although syntaxin alone conferred no GABA transport. In
addition, these GAT1- and syntaxin 1a-coinjected oocytes dis-
played upregulated transport in response to PMA. This upregu-
lation was also reflected by an increase in surface transporter
number and an increase in amounts of protein on the plasma
membrane as assessed by immunoblot (data not shown). The
specificity of syntaxin 1a action was confirmed by blocking the
effect of syntaxin 1a by injection of BoNt /C. Thus, at least one
trafficking-associated protein, syntaxin 1a, is itself sufficient to
confer regulation at high levels of GAT1 expression.
Docking and fusion proteins are required for
modulation of GABA transport
The effect of synaptophysin and syntaxin 1a antisense oligonucle-
otides on modulation of GAT1 activity, coupled with the evidence
that these proteins are involved in synaptic vesicle trafficking and
docking for neurotransmitter release (for review, see Scheller,
1995; Sudhof, 1995), suggested that related proteins may also
influence basal expression of GAT1 and/or modulation of GAT1.
Recently, several classes of clostridial toxins, long known to be
potent inhibitors of neurotransmitter release, have been identified
as endoproteases with a specificity for proteins of the docking and
fusion complex of synaptic vesicles (for review, see Huttner,
1993). We selected BoNt /A, BoNt /B, and BoNt /C, which proteo-
lytically cleave synaptosomal-associated protein (SNAP)-25, syn-
aptobrevin, and syntaxin, respectively, and assessed their action
on basal expression and modulation of GAT1 (in the absence of
rat brain mRNA coinjection).
Because we had determined that syntaxin 1a was involved in
GAT1 regulation, we used syntaxin 1a inactivation to verify clos-
tridial toxin action in oocytes. Furthermore, homologous BoNt /C
substrates exist in non-neuronal cells (Bennett et al., 1993).
GAT1-expressing oocytes were microinjected with PMA, BoNt /C,
or both, and analyzed for transport activity by uptake assay or for
protein localization by subcellular fractionation. BoNt /C signifi-
cantly reduced basal [3H]GABA transport by 47% (Student’s t
test, p , 0.05) and similarly eliminated the PMA-induced increase
(Fig. 5A, top). The subcellular localization of GAT1 after BoNt /C
treatment is shown in Figure 5A (middle and bottom). BoNt /C
affected the basal localization of GAT1, reducing GAT1 on the
plasma membrane from 21% of total transporters during the basal
state to 4%. Coinjection of BoNt /C with PMA also blocked the
dramatic 10-fold shift in transporters translocated to the plasma
membrane observed with PMA alone.
SNAP-25 is localized predominantly in presynaptic membranes
and is required for synaptic vesicle exocytosis and constitutive
vesicle exocytosis in neurons (Sollner et al., 1993); it is selectively
cleaved by BoNt /A (Blasi et al., 1993a). To determine whether
SNAP-25 affects functional expression of GAT1 and modulation
by PMA, oocytes expressing GAT1 were untreated (basal), mi-
croinjected with either PMA or BoNt /A, or both. Forty-five
minutes after drug injection, a subset of injected oocytes was
homogenized for subcellular fractionation of membranes, and a
parallel group was assayed for [3H]GABA transport (Fig. 5B).
BoNt /A alone significantly reduced GABA transport to 63% of
basal levels (Student’s t test, p , 0.05). BoNt /A coinjected with
PMA not only blocked the twofold increase in uptake observed
with PMA alone, but again reduced basal transport below that of
control levels (Fig. 5B, top). The decrease in uptake activity
accompanied a change in the subcellular distribution of transport-
ers located in both plasma membrane and cytoplasmic vesicle
fractions. In the basal state, 48% of total GAT1 protein was found
on the plasma membrane, and 52% was located in cytoplasmic
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Figure 4. Synaptophysin and syntaxin 1a alter the function and
expression of GAT1. A, Coinjection of synaptophysin or syntaxin 1a
antisense oligonucleotides in oocytes injected with GAT1 and total rat
brain mRNA eliminates PMA-induced modulation. Oocytes were
coinjected with 5 ng of GAT1 and 50 ng of rat brain RNA. In addition,
oocytes were also injected with 25 ng of either sense (control) or
antisense oligonucleotides to synaptophysin or syntaxin 1a at the time
of RNA injection, and again 24 hr later. Oocytes were assayed 72 hr
after RNA injection. The PMA concentration was 400 nM. For oocytes
injected with syntaxin 1a oligonucleotides, a subset of oocytes was
injected with 1 ng of BoNt/C. Data are mean 6 SEM. Oocytes (6
oocytes/condition) were assayed for [3H]GABA uptake 15 min after
injection of a control solution (open bars), PMA (hatched bars), or
PMA and BoNt/C ( filled bars). Assay time was 15 min. B, Summary
data for the effect of sense and antisense synaptophysin oligonucleo-
tide injection. Expression level is quantified as the amount of
[3H]GABA uptake in GAT1/rat brain-injected oocytes additionally
injected with antisense ( filled squares) or sense (open squares) oligo-
nucleotides (abscissa). The change in uptake induced by 400 nM PMA
(ordinate) is plotted as a percentage of vehicle-only injected oocytes. For comparison, the results for oocytes injected with only
GAT1 are included (open circles). Each data point represents the mean 6 SEM for three to seven oocytes. Different expression
levels were obtained by performing the assay at different times after RNA injection. C, PMA-induced changes in oocyte plasma
membrane number as assessed by measurement of charge movements. Calculations are described in Materials and Methods.
Measurements were made on GAT1/rat brain mRNA-expressing oocytes injected with either sense ( filled circles) or antisense
(open circles) oligonucleotides. The data presented are from individual oocytes with comparable initial charge movements and
are representative of five oocytes /condition. D, Coexpression of syntaxin 1a with GAT1 permits PMA-induced modulation at
higher expression levels. Oocytes were assayed 48 hr after RNA injection. Data are mean 6 SEM. Oocytes (5 oocytes /condition)
were assayed for [3H]GABA uptake 15 min after injection of a control solution (open bars), 400 nM PMA (hatched bars), or PMA
and 1 ng of BoNt /C ( filled bars).
2974 J. Neurosci., May 1, 1997, 17(9):2967–2979 Quick et al. • Functional Regulation of a GABA Transporter
Figure 5. Effect of botulinum toxins on basal GABA transport and on PMA-induced translocation of GAT1. A–C, GAT1-expressing oocytes were
untreated (Basal ) or injected with 400 nM PMA, botulinum toxin, or both. A subset of these oocytes was assayed 50 min later for [3H]GABA uptake (top).
The uptake data represent the mean 6 SEM for five oocytes /condition. The assay time was 15 min. Subcellular fractionation was performed on parallel
oocyte samples (25–40 oocytes /sample) and analyzed by equilibrium sedimentation on discontinuous sucrose gradients as described in Materials and
Methods. The membrane pellets were resuspended, subjected to SDS-PAGE, and transferred to nitrocellulose, and GAT1 protein present in plasma
membrane (P) and cytoplasmic vesicle (V ) fractions was visualized by immunoblotting (bottom). Densitometry was performed on the immunoblots, and
band densities for the plasma membrane and cytoplasmic vesicle fractions are plotted as a percentage of the total density within each treatment group
(P 1 V ) (middle). These results are a representative example from two separate experiments. A, Results using BoNt /A (50 ng /oocyte). B, Results using
BoNt /C (1 ng /oocyte). C, Results using BoNt /B (1 ng /oocyte). D, Inhibition of the botulinum toxin effects on basal and PMA-induced GABA transport
by o-phenanthroline. GAT1-expressing oocytes were untreated (Basal ) or injected with 400 nM PMA, 50 ng of BoNt /A, or both. One-half of each group
were additionally injected with o-phenanthroline to a final concentration of 1 mM.
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vesicles. After treatment with BoNt /A, the distribution of trans-
porters shifted to 21 and 79% located on the plasma membrane
and in vesicles, respectively (Fig. 5B, middle and bottom). Thus,
inhibition of SNAP-25 and of syntaxin-related proteins (each
located on the plasma membrane) affects both the basal distribu-
tion and the PMA-induced distribution of GAT1.
Synaptobrevin, a component of synaptic vesicles, is believed to
function in the secretory pathway (for review, see Buckley, 1994)
via interactions with syntaxin, SNAP-25, and the N-ethyl-
maleimide-sensitive fusion protein /soluble NSF attachment pro-
tein complex (Sollner et al., 1993); cellubrevin plays a similar role
in non-neuronal cells. Both synaptobrevin and cellubrevin are
substrates for BoNt /B (Schiavo et al., 1992; McMahon et al.,
1993). GAT1-expressing oocytes were treated with PMA,
BoNt /B, or both, and assayed for transport activity and subcellu-
lar distribution. BoNt /B alone had no significant effect on basal
transporter activity (Student’s t test, p , 0.20) (Fig. 5C, top).
Tenfold and 50-fold higher concentrations of BoNt /B also failed
to affect basal transporter activity (data not shown). Consistent
with the lack of BoNt /B effects on basal transport, no difference
in the subcellular localization of GAT1 in untreated and BoNt /
B-treated oocytes was observed (Fig. 5C, middle and bottom).
However, similar to results with BoNt /C and BoNt /A (Fig. 5, A
and B, respectively), coinjection of BoNt /B with PMA resulted in
a block of the 2.5-fold PMA-induced increase (Fig. 5C, top). The
fractionation results showed that BoNt /B had its effect by pre-
venting the translocation of transporters to the plasma membrane
(Fig. 5C, middle and bottom). Therefore, a cellubrevin-related
molecule is involved in the PMA-induced translocation of GAT1
but not in the basal level expression of GAT1. This result con-
trasts with that observed for the plasma membrane-located pro-
teins syntaxin and SNAP-25, which affect the basal level GAT1
expression as well.
To confirm that the actions of the three toxins were attributable
to proteolytic cleavage of their substrates rather than to nonspe-
cific effects on the oocytes, we used o-phenanthroline, which
blocks botulinum toxin effects by chelating the Zn21 necessary for
the proteolytic activity of the toxins. The results for BoNt /A are
shown in Figure 5D; comparable results were seen for BoNt /B
and BoNt /C (data not shown). [3H]GABA uptake was examined
in GAT1-expressing oocytes that were PMA-injected, toxin-
injected, or injected with both. The results obtained were com-
pared with oocytes that were additionally injected with a final
concentration of 1 mm o-phenanthroline. As seen previously (Fig.
5B), BoNt /A reduced both the basal uptake of [3H]GABA in
GAT1-expressing oocytes and eliminated the PMA-induced in-
crease in uptake activity. In both cases, the addition of
o-phenanthroline only slightly reduced uptake but significantly
reduced the BoNt /A effects. These results suggest that the toxins
exert their effects on GABA transport in oocytes via their proteo-
lytic activity.
Removal of a leucine heptad repeat in GAT1 alters
GAT1 regulation
The antisense and toxin data suggested that the regulation of
GAT1 distribution and function is associated with proteins in-
volved in trafficking and recycling of proteins in both neural and
non-neural cells. In other proteins, including glucose transporters,
regions containing repeating leucine motifs play a role in targeting
and trafficking (Asano et al., 1992; Matter et al., 1994; Verhey and
Birnbaum, 1994; Cool et al., 1995). The primary sequence of
GAT1 contains a leucine heptad repeat sequence. Site-directed
mutagenesis (leucine to alanine) at positions 83, 90, 97, and 104
was performed, and the resulting mutant GAT1 cRNA was in-
jected into oocytes (Fig. 6). As expected, in oocytes injected with
wild-type GAT1, GABA transport increased in the presence of
PMA, and this increase correlated with a movement of GAT1
from intracellular stores to the plasma membrane as assessed by
Western blot. However, in oocytes expressing mutant transporters
at a comparable expression level, PMA did not induce an increase
in GABA transport. These data are consistent with immunoblot
data showing that, in the basal state, most of the protein is already
at the plasma membrane, and therefore further PMA-induced
modulation by translocation is impossible.
We also asked whether the leucine mutations eliminated sus-
ceptibility to modulation by decreases in PKC. We performed
experiments using the PKC inhibitor bisindolylmaleimide, which
causes a shift in the distribution of wild-type GAT1 from the
plasma membrane fraction to the cytoplasmic fraction (Corey et
al., 1994). Immunoblot results are shown in Figure 6B. The
increase in wild-type GAT1 protein found in the cytoplasmic
vesicle fraction (and concomitant decrease in GAT1 protein
found in the plasma membrane fraction) after bisindolylmaleim-
Figure 6. Elimination of a leucine heptad repeat in GAT1 alters transporter
regulation. A, Oocytes were injected with wild-type GAT1 cRNA or cRNA
encoding a mutant GAT1 in which four leucines were changed to alanine (at
positions 83, 90, 97, and 104). [3H]GABA uptake assays were performed 48
hr later on both basal (open bars) and PMA-treated (hatched bars) oocytes.
The PMA concentration was 400 nM. The uptake data represent the mean 6
SEM for 15 oocytes/condition. Subcellular fractionation was performed on
parallel oocyte samples (25 oocytes/sample) and analyzed by equilibrium
sedimentation on discontinuous sucrose gradients as described in Materials
and Methods. The membrane pellets were resuspended, subjected to SDS-
PAGE, and transferred to nitrocellulose, and GAT1 protein present in
plasma membrane (P) and cytoplasmic vesicle (V) fractions was visualized by
immunoblotting. B, Immunoblots after subcellular fractionation of oocytes
injected with cRNA either for wild-type GAT1 or for the quadruple leucine-
to-alanine mutant described in A. Fifteen minutes before fractionation, oo-
cytes were injected with either 50 nl of vehicle solution (Basal) or 100 nM
bisindolylmaleimide (Bis).
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ide treatment does not occur for the mutant GAT1 protein. These
data suggest that the region of GAT1 containing a leucine heptad
repeat motif plays a role both in basal expression of the protein
and its susceptibility to regulation by PKC. One intriguing possi-
bility is that this region of GAT1 is required for the entry of the
GAT1 protein into a compartment utilizing PKC-regulated traf-
ficking proteins.
Additionally, we examined PMA-induced modulation for a
number of mutant GAT1 proteins in which leucines in this region
of the protein were mutated individually, in pairs, or in triplicate.
These data are summarized in Table 1 for oocytes with low GAT1
expression levels (between 1 and 10 fmol /oocyte/min). No differ-
ences in PMA-induced increases in GABA uptake were found
when one or two leucines were mutated; removal of any three
leucines abolished the PMA-induced modulation.
DISCUSSION
We have sought to create a model system for examining neuro-
transmitter transporter regulation that is more favorable than the
presynaptic terminal, where the transporter is normally expressed,
to permit physiological, biochemical, and cell biological measure-
ments and nucleic acid-based reconstitution of wild-type and
mutant transporters. In the oocyte expression system, our data
show that the surface level of GAT1 is subject to regulation by
mechanisms and molecules, such as clostridial toxin substrates,
synaptophysin, syntaxin, and kinases, that regulate many other
membrane components of the presynaptic terminal. Additionally,
the data show that GAT1 regulation in this model system requires
residues homologous to those involved in protein–protein inter-
actions during trafficking of facilitated glucose transporters. These
two sets of facts about GAT1 regulation strongly suggest that
neurons also have the capacity to regulate GAT1 levels at the
presynaptic terminal and that this regulation involves mechanisms
and protein domains similar to those that govern the surface level
of other transporters in non-neuronal cells. This possible regula-
tion takes on added significance because of the hypothesis that
surface density of neurotransmitter transporters is a crucial com-
ponent in terminating the synaptic event (Mager et al., 1993, 1996;
Sarantis et al., 1993; Lester et al., 1996).
Role of trafficking-related proteins
Synaptophysin, syntaxin, and other substrates for botulinum tox-
ins are associated with specific aspects of basal GAT1 trafficking,
PKC-mediated translocation, and functional surface expression.
These results suggest a trafficking pathway in oocytes that is
analogous to the classical regulated exocytotic pathway of trans-
mitter release, although this suggestion is tentative because traf-
ficking pathways in oocytes have not been well characterized.
These data also suggest a close interaction between factors that
control secretion and the components regulating neurotransmitter
uptake.
The GAT1 transporter expressed at low levels in oocytes is
targeted primarily to a PKC-sensitive secretory pathway and
stored intracellularly. At high GAT1 expression levels, the ability
to modulate transporter function decreases, although the PMA-
induced translocation to the plasma membrane fraction still oc-
curs (Corey et al., 1994). The present data show that the addition
of rat brain mRNA to oocytes expressing high levels of GAT1
rescues functional modulation, and that secretion-related pro-
teins, such as synaptophysin and syntaxin, mediate this effect. In
the most likely interpretation of these data, these proteins are
among several components necessary for the translocation of
GAT1, and rat brain mRNA complements the endogenous ma-
chinery of the oocyte for performing this task. Synaptophysin is a
critical component in a neurotransmitter release pathway ex-
pressed in oocytes via rat brain RNA (Alder et al., 1992).
Through the use of clostridial toxins that act on these proteins,
we have identified components of the vesicle docking /fusion ap-
paratus required for expression and modulation of GAT1 func-
tion in oocytes. Both a BoNt /C substrate, presumably homologous
to the syntaxins, and a BoNt /A substrate, such as SNAP-25, are
necessary for regulation of GAT1 during constitutive recycling as
well as for PMA-induced modulation of the transporter. Interest-
ingly, a BoNt /B substrate such as synaptobrevin or cellubrevin is
not required for constitutive recycling of the GAT1 transporter,
but is necessary for the PKC-regulated translocation of the trans-
porter to the cell surface. This suggests that the requirements for
components of the docking /fusion complex may be different for
constitutive recycling and regulated expression of plasma mem-
brane proteins. It is also consistent with the findings of Link et al.
(1993), in which it is shown that cellubrevin is not required for
fusion of vesicles with endosomes in baby hamster kidney cells.
Role of leucine heptad repeat motifs
Leucine zipper motifs were first identified as regions that mediate
DNA–protein binding (Landschulz et al., 1988). More recently,
the a-helical structures presumed to be formed by leucine heptad
repeats have been shown to mediate a number of protein–protein
interactions: (1) Heptad repeats occur in regions identified in
coiled-coil relationships between SNAP-25 and syntaxin (Chap-
man et al., 1994). (2) Leucine heptad repeats in transmembrane
segments of the hemagglutinin-neuraminidase protein (McGinnes
et al., 1993) and gp41 (Bernstein et al., 1995) are responsible for
oligomer formation. (3) Mutagenesis of leucine heptad repeats in
the heat shock protein HSF2 results in subcellular mislocalization
of the protein (Sheldon and Kingston, 1993). In our studies of
GAT1, removal of the leucine heptad repeat located in the second
putative transmembrane domain does not appear to affect trans-
porter function directly, but still affects transporter localization
and modulation. Thus, removal of the leucine heptad repeat (1)
causes a redistribution of the transporter such that the majority of
the protein is located on the plasma membrane, and (2) eliminates
modulation of the transporter by PKC. We speculate that the
interaction of this region with other cellular proteins may play a
role in the targeting of GAT1 (Ahn et al., 1996) and other
transporters to specific regions of the plasma membrane. Mem-
bers of the glucose transporter family also contain a well con-
Table 1. Effect of leucine mutations on PMA-induced GABA uptake
Position of Leu 3 Ala Mutation
PMA-induced
[3H]GABA uptake
(% of basal,
mean 6 SEM)83 90 97 104
Wild type 212 6 31
X 226 6 18
X 198 6 25
X 210 6 17
X 186 6 21
X X 191 6 27
X X 173 6 14
X X X 90 6 21
X X X 108 6 19
X X X X 95 6 14
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served leucine heptad repeat in the second putative transmem-
brane domain (White and Weber, 1989), and in studies of
chimeric transporters, amino acid residues in this region are
partially responsible for targeting of glucose transporter isoforms
to intracellular or plasma membrane compartments (Asano et al.,
1992). Several other members of the neurotransmitter transporter
family display a moderately well conserved leucine heptad motif
in transmembrane domain 2 (Giros and Caron, 1993).
Endocytosis versus exocytosis?
Net membrane trafficking is the sum of endocytotic and exocytotic
events. We believe the PMA-induced redistribution of GAT1
results primarily from specific increased exocytosis of GAT1,
rather than from decreased endocytosis, for the following reasons.
(1) The GAT1 increase occurs despite the general ;35% endo-
cytotic decrease in membrane area induced by PKC activation. (2)
For the Na1/K1–ATPase, the trafficking of which has been stud-
ied in oocytes, basal endocytosis occurs at only ;10% per hour
[Schmalzing et al. (1995), their Fig. 4]. Thus, even if endocytosis
were to stop completely, this effect would be too small to account
for the present data.
As discussed previously (Corey et al., 1994), the PMA-induced
translocation of GAT1 could be explained either by increasing the
rate of constitutive exocytosis or by stimulating secretion from a
stored pool of transporters in a regulated pathway. Evidence for
the former hypothesis comes from studies in which PMA affects
trafficking rates (Cardone et al., 1994). However, our data suggest
a contribution from a regulated pathway for the following reasons.
(1) The involvement of synaptophysin and of botulinum toxin
substrates points to the role of proteins generally thought to
participate in regulated exocytotic pathways. (2) Regulation by
calcium (our unpublished observations), a defining characteristic
of regulated secretion pathways, occurs in GAT1 translocation.
Addressing the relative contributions of exocytotic and endocy-
totic pathways in transporter regulation and delineating the spe-
cific components in oocyte trafficking pathways are goals of future
experiments.
The demonstration that a neurotransmitter transporter heter-
ologously expressed in oocytes is targeted to a trafficking pathway
involving elements in common with the well characterized path-
way for neurotransmitter release underscores the concept that the
molecular machinery for secretion is conserved from yeast to
neurons (Bennett and Scheller, 1993). Scheuner et al. (1992)
demonstrated that the constituents of chromaffin granule mem-
branes are sufficient to reconstitute exocytosis when injected into
Xenopus oocytes and proposed that the ability to substitute mam-
malian and amphibian secretory pathway components suggests
substantial biochemical conservation of the exocytotic pathway.
Homologs for both synaptobrevin and syntaxin have been found
in non-neuronal tissue (Bennett et al., 1993; McMahon et al.,
1993), including glucose transporter-containing vesicles of rat
adipocytes (Cain et al., 1992). These findings suggest a general
mechanism for membrane trafficking shared by all cells. Not only
are component proteins conserved, but the actual pathway of
secretion may have evolved from a more basic mechanism of
membrane repair. Steinhardt et al. (1994) demonstrated that after
injury to the cell membrane of sea urchin embryos and fibroblasts,
resealing of the membrane occurs by a mechanism involving
vesicle delivery, docking, and fusion similar to the exocytosis of
neurotransmitters.
Modulation of neurotransmitter uptake by redistribution of
transporters from cytoplasmic stores to the plasma membrane has
important implications for the proposed function of these trans-
porters in terminating and spatially localizing synaptic transmis-
sion. Our data show that the density of GABA transporters at the
plasma membrane can be regulated by a mechanism involving
second-messenger cascades that occur in neurons, and that do-
mains that control targeting in other transporter families do so for
GAT1 as well. In addition, we show that modulation of the GABA
transporter expressed in oocytes occurs via vesicular trafficking
and includes components similar to those found in secretion. This
system will also be useful for examining exocytotic events in
vesicle docking and fusion, and it may provide insight into the
participation of transporters in this process.
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